References
- National Public Radio. 2017 [cited 2017 April 4]. Available from: http://www.npr.org/sections/health-shots/2017/01/17/509507035/high-prices-for-orphan-drugs-strain-families-and-insurers
- Financial Times. 2017 [cited 2017 April 4]. Available from: https://www.ft.com/content/2016a758-d674-11e6-944b-e7eb37a6aa8e,
- EvaluatePharma. 2017. Orphan drug 2017 report. [cited 2017 April 4]. Available from: http://www.evaluategroup.com/public/Reports/EvaluatePharma-Orphan-Drug-Report-2017.aspx
- Axene DV (2003). Health care affordability – a valuable concept in understanding our health system care challenges. Health Section News, Society of Actuaries, 45, 20–22. [cited 2017 April 24]. Available from: https://www.soa.org/Search.aspx?q=health%20section%20news%202003%20axene&pagesize=10&sortby=rank
- De Savigny D, Adam T. Systems thinking for health systems strengthening. Geneva: World Health Organization; 2009.
- Stolk P, Willemen MJC, Leufkens HGM. “Rare essentials”: drugs for rare diseases as essential medicines. Bull World Health Organ. 2006;84:9.
- Gammie T, Lu CY, Babar ZU-D. Access to orphan drugs: a comprehensive review of legislation, regulation and policies in 35 countries. Plos One. 2015 [cited 2015 Oct 9];10:e0140002.
- Short H, Stafinski T, Menon D. A national approach to reimbursement decision-making on drugs for rare diseases in Canada? Insights from across the ponds. Healthc Policy. 2015;10(4):25–46.
- Parsons T. The social system. London: Routledge Press; 1951.
- Bloomberg Briefs (2017). BioMarin prices orphan drug at $702,000, promises big discounts. [cited 2017 May 22]. Available from: https://www.bloomberg.com/news/articles/2017-04-27/biomarin-prices-orphan-drug-at-702-000-promises-big-discounts